Park Square is pleased to announce the placement of Andrew Eisen as Vice President of Translational Medicine at Rexahn Pharmaceuticals. Rexahn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of cancer.
Eisen most recently served as the Senior Director, Translational Medicine at Acorda Therapeutics. Previously, he served as the Owner/Consultant at Translational Strategic Consultants. Earlier, he served as the Senior Director at Eisai Oncology Product Creation Systems. Prior to then, he served as the Director, Clinical Pharmacology & Experimental Medicine at Daiichi-Sankyo Pharma Development.
Eisen received his A.B. from Princeton University and M.D. and Ph.D. from University of Pennsylvania.
Park Square Executive Search serves companies and institutions that are shaping the world through discovery, innovation and growth. Our clients are leading life sciences and healthcare organizations, technology companies, major research universities, and venture capital and private equity firms, including their portfolio companies. We place board members, chief executive officers, C-suite executives, and academic leaders.